Proteomics can help address the COVID-19 pandemic

To combat COVID-19 we must move beyond the “+/- diagnostic moment” to measure systemic host changes in the infection and human disease cycle, reliably and cost-effectively, in individuals and across populations.

We believe proteomics using SomaLogic’s well-validated SomaScan Assay technology has a key part to play in providing the knowledge we need to effectively address the pandemic.

We are making our SomaScan technology widely available to biopharma and academic COVID-19/SARS-CoV-2 scientists and clinicians under highly simplified terms and conditions.

We hope to work with these researchers from around the world to assay every eligible clinical sample and share the resulting assay data as broadly as possible to hasten an effective global response to this pandemic.

In addition, we know that not all investigators will be able to cover even the basic costs of assaying COVID-19 samples, and we do not have sufficient resources ourselves to bear that burden alone. Therefore, we are seeking additional funding partners, private and public, to ensure that we can analyze as many samples for as many researchers as possible.

Interested in working with us to combat COVID-19?

 

How the SomaScan technology can help COVID-19 researchers

SomaLogic and many of our current clients and collaborators know that this powerful technology can and should play a unique role in addressing the COVID-19 crisis. We are making it broadly available to COVID-19/SARS-CoV-2 researchers and drug developers because our proprietary technology will help them on multiple fronts, including in the following “Use Cases”:

USE CASE 1: Learning how to predict early who is going to progress and develop severe illness from the disease

Action: Discover protein expression patterns in patients with mild/moderate symptoms that can provide the basis for developing a rapid diagnostic test to identify who will go on to develop life-threatening illness, and who won’t.

IMPORTANCE: Determine who needs hospital care or protective drug therapy. Enable shorter, faster clinical trials enriched for people who progress to severe illness. Increase the success of clinical trials by enabling earlier treatment that is more likely to succeed – before the onset of severe organ damage. When potentially effective drugs are available but in limited supply, identify who needs them most. When used as a rule-in or rule-out test, enable more efficient resource management for healthcare systems.

See examples of this use case

USE CASE 2: Identifying disease complication sub-types in those at risk for severe illness

Action: Discover protein expression patterns in patients that will become the basis of a test to help doctors determine which patient will develop specific clinical complications – e.g., respiratory failure alone, respiratory failure with cardiac myopathy, or other complications. Similarly to Use Case 1, these protein signatures can provide the basis for developing a rapid diagnostic test that can translate findings into patient care.

IMPORTANCE: Help clinicians understand in real-time who will develop certain problems, and potentially impact both disease treatment planning, the allocation of specific therapies, and resource utilization in constrained delivery situations.

See examples of this use case

USE CASE 3: Repurpose existing approved drugs by matching them with identified biological drivers of downstream effects of COVID-19

Action: Discover protein expression patterns that show which dominant biological systems are driving adverse secondary effects of infection; match these to the mechanisms of existing drugs; translate into patient care.

IMPORTANCE: Accelerate the availability of effective treatments already known to be safe.

See examples of this use case

USE CASE 4: Rapidly identify protein targets for new drug candidates to address the effects of COVID-19

Action: Discover new drug targets by relating changes in individual proteins to disease severity and prognosis (often in conjunction with genomic information); enable Pharma to act upon the results.

IMPORTANCE: New COVID-19 drug leads.

See examples of this use case

USE CASE 5: Accelerate clinical trials and provide early indication of efficacy of new COVID-19 drug candidates

Action:Apply protein expression patterns discovered in Use Cases 1 and 2 (relating to severity, prognosis and sub-phenotype) in clinical trials to rapidly determine whether a drug will be effective, or not. Protein patterns discovered during these studies can also be used to demonstrate mechanistic proof-of-concept, exposure response (for dose setting), and the existence of undesirable off-target effects.

IMPORTANCE: Accelerate new drug development and clinical trials (SomaLogic has run tens of thousands of these types of patient samples through the platform already with pharma clients).

See examples of this use case

USE CASE 6: Accelerate vaccine development

Find protein expression patterns that detect or predict clinical response to a vaccine, or immune response, that is compatible with longer-term clinical effect.

IMPORTANCE: Accelerate vaccine evaluation and development efforts.

See examples of this use case

Note: The SomaScan Assay protein measurements are indicated for Research Use Only (RUO). Use of these protein signatures for patient management would require further regulatory qualification and/or translation to a near-patient assay platform.